🇺🇸 Concomitant treatment in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Abortion Spontaneous — 1 report (10%)
2. Anal Squamous Cell Carcinoma — 1 report (10%)
3. Cytolytic Hepatitis — 1 report (10%)
4. Escherichia Infection — 1 report (10%)
5. Foetal Malformation — 1 report (10%)
6. Hyperkalaemia — 1 report (10%)
7. Hyponatraemia — 1 report (10%)
8. Influenza Like Illness — 1 report (10%)
9. Liver Function Test Abnormal — 1 report (10%)
10. Maternal Drugs Affecting Foetus — 1 report (10%)

Source database →

Frequently asked questions

Is Concomitant treatment approved in United States?

Concomitant treatment does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Concomitant treatment in United States?

R-Pharm International, LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.